Renaissance Capital logo

Candel Therapeutics Priced, Nasdaq: CADL

Phase 3 biotech developing oncolytic viral immunotherapies for cancer.

Industry: Health Care

Latest Trade: $1.58 0.00 (0.0%)

First Day Return: -12.5%

Return from IPO: -80.3%

Industry: Health Care

We are a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Our most advanced product candidate, CAN-2409, is an off-the-shelf adenovirus product candidate combined with the prodrug valacyclovir that has generated promising clinical activity across a range of solid tumor indications, including our lead indication of prostate cancer. We are currently conducting, as part of our most advanced CAN-2409 program, a Phase 3 clinical trial in the United States under a Special Protocol Assessment, or SPA, with the FDA for CAN-2409 in combination with the prodrug valacyclovir in patients with newly diagnosed localized prostate cancer who have an intermediate or high-risk for progression. We expect to complete enrollment for this trial in the third quarter of 2021 with a final data readout in 2024. We are also evaluating CAN-2409 in newly diagnosed high-grade glioma. The FDA has granted CAN-2409 Fast Track designation for use in this setting in combination with standard of care surgery and chemoradiation. We intend to initiate a potential registrational Phase 3 trial in this indication in the first half of 2022.
more less
IPO Data
IPO File Date 06/25/2021
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 9.0
Deal Size ($mm) $72
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/26/2021
Offer Price $8.00
Price Range $8.00 - $8.00
Offer Shares (mm) 9.0
Deal Size ($mm) $72
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Credit Suisse
more
Company Data
Headquarters Needham, MA, United States
Founded 2003
Employees 50
Website www.candeltx.com

Candel Therapeutics (CADL) Performance